Literature DB >> 4016745

Comparative properties of five human ovarian adenocarcinoma cell lines.

R N Buick, R Pullano, J M Trent.   

Abstract

We describe the derivation of three human ovarian carcinoma cell lines and the comparison of their properties with two previously described cell lines of like histology (SKOV-3 and CAOV-3). Two of the new lines (HOC-1 and HOC-7) were derived from separate ascites tumors (at 9-month intervals) of a patient with well-differentiated serous adenocarcinoma of the ovary. The third new line, HEY, was derived from a human ovarian cancer xenograft (HX-62) originally grown from a peritoneal deposit of a patient with moderately differentiated papillary cystadenocarcinoma of the ovary. The cell lines demonstrated differential ability to grow in semisolid culture and as xenografts in immunologically deprived CBA/CJ mice. Dose-response curves were generated for clonogenic cell survival of cells exposed to common chemotherapeutic agents; one of the lines (HEY) shows a degree of resistance to the alkylating agent cis-diamminedichloroplatinum(II) (cis-platinum). Common karyological features included structural abnormalities of chromosomes 3 and 11. Heterogeneity of expression of ovarian tumor-associated antigens was documented.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4016745

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  114 in total

1.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

2.  Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Authors:  Robert Cornelison; Zachary C Dobbin; Ashwini A Katre; Dae Hoon Jeong; Yinfeng Zhang; Dongquan Chen; Yuliya Petrova; Danielle C Llaneza; Adam D Steg; Laura Parsons; David A Schneider; Charles N Landen
Journal:  Clin Cancer Res       Date:  2017-08-04       Impact factor: 12.531

3.  Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Authors:  Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

4.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

5.  Automatic quantitation of cell colonies on petri dishes by computerized image analysis.

Authors:  A Bollea; M Masseroli; A Nicotra; P Beccaglia; S Sen; E Erba; G Balconi
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

6.  Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Authors:  Adam D Steg; Ashwini A Katre; Blake Goodman; Hee-Dong Han; Alpa M Nick; Rebecca L Stone; Robert L Coleman; Ronald D Alvarez; Gabriel Lopez-Berestein; Anil K Sood; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

7.  Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.

Authors:  Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

8.  Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Authors:  Kalpana Mujoo; Masayuki Watanabe; Junichi Nakamura; Abdul R Khokhar; Zahid H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

9.  Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Authors:  Charles N Landen; Tae-Jin Kim; Yvonne G Lin; William M Merritt; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Nicholas B Jennnings; Michael S Kinch; David Tice; Anil K Sood
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Enforced Expression of METCAM/MUC18 Decreases In Vitro Motility and Invasiveness and Tumorigenesis and In Vivo Tumorigenesis of Human Ovarian Cancer BG-1 Cells.

Authors:  Guang-Jer Wu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.